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Fidaxomicin (FDX) is a marketed antibiotic for the treatment of Clostridioides difficile infec-
tions (CDI). Fidaxomicin displays antibacterial properties against many Gram-positive bac-
teria, yet the application of this antibiotic is currently limited to treatment of CDI.
Semisynthetic modifications present a promising strategy to improve its pharmacokinetic
properties and also circumvent resistance development by broadening the structural diversity
of the derivatives. Here, based on a rational design using cryo-EM structural analysis, we
implement two strategic site-selective catalytic reactions with a special emphasis to study
the role of the carbohydrate units. Site-selective introduction of various ester moieties on
the noviose as well as a Tsuji–Trost type rhamnose cleavage allow the synthesis of
novel fidaxomicin analogs with promising antibacterial activities against C. difficile and
Mycobacterium tuberculosis.
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idaxomicin (1, tiacumicin B, lipiarmycin A3) constitutes an
18-membered narrow-spectrum macrolide antibiotic that was
extracted from several actinomycetes1–7 and shows anti-
bacterial properties against mainly Gram-positive bacteria8, in
particular against methicillin-resistant Staphylococcus aureus9,
multidrug-resistant Mycobacterium tuberculosis7, and Clostridioides
difficile10–12. To date, the clinical use is limited to the treatment of
C. difficile infections, the main cause of hospital-acquired diarrhea,
against which fidaxomicin was approved by the FDA in 201113–17.
Fidaxomicin inhibits the RNA polymerase (RNAP) via a new
mechanism of action, rendering second-generation derivatives
thereof particularly attractive18–20. Resistance development in bac-
teria accelerated over the last few decades and new mechanisms of
resistance have emerged, which calls for the development of anti-
biotics with unique mechanisms of action21.
Globally, an estimated 10.0 million people fell ill with tuber-
culosis (TB) in 2019 and more than 1 million people died of it.
Drug-resistant TB continues to be a public health threat. Almost
half a million people developed rifampicin-resistant TB (RR-TB),
of which 78% were multidrug resistant (MDR)22. Multidrug-
resistant M. tuberculosis strains exhibit resistance toward the two
most effective drugs, isoniazid and rifampicin, of the four drug
standard treatment regimen. Alarmingly, in some countries, more
than 50% of previously treated TB cases had MDR/RR-TB.
Patients suffering from MDR-TB require a treatment with
second-line drugs, which are less effective, more toxic, and more
expensive. New treatment regimens combining compounds with
novel mode of actions like bedaquiline23 and repurposed drugs
(linezolid) are currently evaluated for the treatment of MDR-
TB24. However, resistant strains were detected soon after
approval of novel drugs25. These findings indicate that the TB
drug-pipeline has to be fueled continuously.
Susceptibility of C. difficile to fidaxomicin remains generally
very high in the clinic, although there have been very few cases
of fidaxomicin-resistant strains emerging26,27, which calls for
the development of second-generation derivatives. Although
fidaxomicin has a high potential to deliver next-generation
antibiotics, there are only few successful approaches
toward new derivatives documented that might broaden
structure–activity relationship (SAR) information and thereby
further extend its application18,28,29. So far, most known
derivatives were obtained through fermentation of gene-
knockout mutants of the producer strain or by chemical
modification of the homoorsellinic acid moiety30–35. Fur-
thermore, several compounds with a similar scaffold were
found along with fidaxomicin (1), some of which lack the
rhamnose-orsellinate and/or the noviose moiety8,36. Those
truncated products missing one of the sugar moieties display
significantly decreased antibiotic activity and thereby point
out the importance of these carbohydrate units37. Interest-
ingly, nature also provides similar scaffolds from other species,
such as mangrolide A (2) and D (3) that possess different
sugar moieties and a similar macrolactone (Fig. 1)38,39. Total
syntheses campaigns of these compounds were started and
successfully accomplished, but not answering the intriguing
question on the role of the carbohydrate units40–44.
Over the past few decades, derivatization of natural products
has been demonstrated to be an effective approach for the
development of new drug candidates21. However, the direct and
selective functionalization of these scaffolds to gain specific SAR
information still remains challenging due to their structural
complexity and broad variety of functional groups. In order to
address these issues, chemo- and site-selective functionalization
recently emerged as a particularly appealing approach45. Espe-
cially, site-selective transition-metal catalysis and organocata-
lysis started to find widespread application in derivatization of
natural products46. In this study, we report on the generation of
novel fidaxomicin derivatives through site-selective catalysis
using a rational design based on a cryo-electron microscopy
(cryo-EM) structure of fidaxomicin binding to M. tuberculosis
RNAP18,19. In this context, semisynthetic strategies for the
modification of fidaxomicin on the noviose- as well as on the
rhamnose-orsellinate moiety were developed: (1) the application
of site-selective organocatalysis for the generation of a library of
3”-acylated fidaxomicin derivatives and (2) a palladium-
catalyzed allylic substitution for the selective cleavage of the
rhamnose-resorcylate moiety. By these strategies, potent fidax-
omicin derivatives that cannot be obtained by genetic mod-
ification could be prepared by chemical synthesis.
Results and discussion
Design based on cryo-EM structural analysis. Previous studies
on the fermentation conditions led to the isolation of several
fidaxomicin congeners with different ester moieties in various
positions on the noviose moiety47. These analogs displayed
decreased antibiotic activities compared to the isobutyric ester
moiety in 4”-position of the parent compound. Intriguingly,
isobutyric ester migration to 3”-position (tiacumicin F) did not
lead to a significant decrease of activity3,5,8, which is in agreement
with the recently disclosed cryo-EM structure. Indeed, there is
an “open space” toward the C3”-hydroxy group that allows
the introduction of functional groups (Fig. 2a, b). In contrast, the
C4”-isobutyric ester fits perfectly into this pocket, but the space
for further modifications in this position is limited. Moreover,
potential interaction with or replacement of water in the active
site constitutes a promising strategy that has already been
demonstrated to be beneficial in drug design48–50. Finally, the
C2”-hydroxy group is involved in multiple hydrogen-bonding
interactions between Arg412 and acetal of the noviose moiety
(Fig. 2c)18,19. Therefore, we expect C2”-acylation of fidaxomicin
derivatives to have a detrimental effect on their bioactivity. Thus,
we hypothesized that modifications on the C3”-hydroxy group of
fidaxomicin constitute a viable design strategy that could lead to
retained or enhanced bioactivity.
On the other part of fidaxomicin, several hydrogen-bonding
interactions of Arg89 with the rhamnose moiety and Lys1101
with the phenolic hydroxy group on the homoorsellinic acid
moiety as well as a cation-π interaction of Arg84 with the
aromatic moiety are present (Fig. 3). Therefore, we aimed to
study the influence of variations on the rhamnose-resorcylate
moiety by modifying this part of the lead structure.
Fig. 1 Glycosylated macrocyclic antibiotics. Structures of fidaxomicin (1), mangrolide A (2), and D (3).
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Modifications on the noviose unit. As discussed above, careful
analysis of the cryo-EM structure of fidaxomicin binding to M.
tuberculosis RNAP and previously reported bioactivities promp-
ted us to consider selective C3”-acylation of the noviose moiety to
gain SAR and potentially identify novel lead structures for drug
discovery. Given the nature and high number of hydroxy groups
in OP1118 (4), a degradation metabolite of fidaxomicin (1), as
well as the lack of data concerning their reactivities and the
chemical fragility of fidaxomicin, site-selective functionalization
of C3”-OH represents an interesting challenge (Fig. 4)51.
In order to address this reactivity challenge, we envisioned to
apply non-enzymatic methodology52. Over the past 15 years,
extensive research efforts led to the development of efficient and
complementary synthetic methods to access regioselective
functionalization of carbohydrate hydroxy groups53. Analysis of
the structural feature of fidaxomicin allowed us to identify the cis-
vicinal diol as a potential platform for catalysis based on
reversible covalent interactions of organoboron compounds.
Indeed, this approach enabled by molecular recognition has
proven to be effective for various transformations54,55. In
addition to provide high regioselectivity, this strategy would also
potentially outcompete the initially more reactive secondary
hydroxy groups (C7-OH/C18-OH) through activation of the cis-
vicinal diol via tetracoordinate borate, therefore avoiding
undesired over-acylation56. In order to study the feasibility of
this transformation, we thus started with the synthesis of the
required precursor for catalysis. Considering the inherently
higher nucleophilicity of phenol moiety, we thus turned our
attention to the synthesis of bisallyl-OP1118 (5) (Fig. 5). Starting
from commercially available fidaxomicin (1), cleavage of the
isobutyrate ester via methanolysis followed by bisallyl protection
of the phenol moiety afforded the starting compound for catalysis
in 71% over two steps.
With the required starting material in hand, we turned our
attention to the screening of initially described ethanolamine ester
of diphenylborinic acid catalyst (Taylor’s catalyst)56 along with a
boronic acid catalyst recently developed by Shimada et al.57.
Under classic conditions, both catalysts afforded conversion to
the desired product (Fig. 6).
Encouraged by this finding, we therefore optimized the
reaction with the Shimada catalyst since it offered slightly higher
catalytic activity in these initial experiments. After screening of all
the parameters of the reaction, we were able to obtain full
conversion (UHPLC/MS analysis) to the desired compound 7
(confirmed by 2D NMR analysis; see Supplementary Fig. 10,
section NMR Spectra) with the conditions depicted in Fig. 7.
Noteworthy, control experiments without catalyst confirming
its presence are essential to ensure high conversion and site-
selectivity. Moreover, the temperature (50 °C) is elevated
compared to previously reported conditions; this is crucial to
achieve complete conversion, which might arise from steric
hindrance or conformational aspects imputed to the gem-
dimethyl moiety of the noviose. Finally, subsequent deprotection
of the allyl moiety in a one-pot two-step manner allowed us to
obtain the desired product 7 in 67% yield (for experimental
details refer to the Supplementary Methods). As expected,
Fig. 2 Cryo-EM structure of fidaxomicin binding to M. tuberculosis RNAP
(PDB ID: 6FBV)18. a Fidaxomicin (cyan), protein (surface representation/
gray). Interaction of C3”-OH with H2O. Limited space around isobutyric
ester moiety. b Detailed view on the binding pocket of fidaxomicin’s
noviose moiety. C3”-OH points toward an “open space.” C4”-isobutyric
ester fits into its pocket. c Detailed view on the interactions of the noviose
part to the protein. C2”-OH is blocked by an interaction with Arg412 (blue).
Fig. 3 Cryo-EM structure of fidaxomicin binding to M. tuberculosis RNAP
(PDB ID: 6FBV)18. Fidaxomicin (cyan), protein (gray), and amino acid
residues (blue). Detailed view on the interactions of the rhamnose-
resorcylate part to the protein.
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attempts to perform this selective C3”-acylation directly with the
compound OP1118 (4) led to the functionalization of the
dichlorohomo-orsellinic acid moiety. Furthermore, experiments
with bisallyl-fidaxomicin51 were performed in order to study C4”-
C3”-diacylated fidaxomicin derivatives. Unfortunately, we were
not able to observe any traces of the desired functionalization
even with stoichiometric amount of the organocatalyst. This
could be explained by the steric hindrance caused by the C4”-
isobutyrate moiety close to the reactive site. With the optimized
conditions in hand, we turned our attention to the delivery of a
library of C3”-acylated fidaxomicin derivatives. First, benzoyl
chloride derivatives with different substitution patterns were
screened. We were pleased to find that ortho-, meta-, and para-
substitutions are tolerated, in addition to electron withdrawing
and electron donating groups 7a–f. Moreover, in some cases
(7d–f), concomitant formation of C2”-benzoylated fidaxomicin
derivatives (confirmed by 2D NMR analysis; see Supplementary
Fig. 28) were observed in not negligible amount. Presumably, the
C2”-benzoylated compounds arise from competing activation of
the second hydroxy group of the cis-vicinal diol rather than
benzoyl migration, as resubmission of the C3”-acylated fidax-
omicin to the reaction conditions did not lead to any
isomerization. Gratifyingly, the C2”/C3”-benzoylated fidaxomicin
mixture was separable by preparative HPLC purification, allowing
us to gain more SAR information. Heteroaromatic scaffolds were
also introduced successfully with almost exclusive regioselectivity
to afford compounds 7j–n in medium to high yield, except the
pyridine moiety 7i. Preliminary interesting biological activities for
the 3-furoyl derivatives 7j led us to explore the impact of the
substitution of the latter, leading to structures 7o–r. In
consideration of the bioactivities of tiacumicin F (7u), we
envisioned to study non-aromatic C3”-acylated fidaxomicin
derivatives. While C3”-acylated fidaxomicin derivatives 7s–t were
obtained in good yield at 10 °C to control overreaction and
degradation (THF ring formation)51, increase of substitution at
carbon α to the carbonyl led to degradation of the reactivity. This
highlighted the crowded environment of the noviose, which is in
line with previous observations made during the optimization of
the reaction conditions. To ensure generation of sufficient
amounts for subsequent biological evaluation, we therefore
increased the amount of Shimada catalyst in the most difficult
cases to afford tiacumicin F (7u) and compounds 7w–ab in
moderate to excellent yields. Notably, stoichiometric amount of
Shimada catalyst provides only slight trace of the desired
compound 7v with pivaloyl chloride. In addition, some
functionalities were successfully introduced, such as methoxy
7ad, chloride 7ag, or terminal alkyne 7ah. Noteworthy, this latter
represents a unique platform for introduction of various triazole
moiety through copper(I)-catalyzed alkyne-azide cycloaddition
(CuAAC). Gratifyingly, dinuclear copper catalyst 21 developed by
Straub et al.58 allowed the formation of derivatives 7ai in excellent
yield. Finally, in order to study the impact of other functional
groups on the biological activity, further electrophiles such as
carbamoyl chloride, chloroformate, and tosylate were tested
under our optimized conditions. Unfortunately, all attempts were
found to be unproductive.
Biological evaluation of C3”-acylated fidaxomicin derivatives.
The biological activities for these 30 fidaxomicin analogs were
evaluated by determination of the minimum inhibitory
Fig. 4 Site-selective acylation of 4. Overview of the strategy.
Fig. 5 Preparation of the catalysis-precursor bisallyl-OP1118 (5). Synthesis of 5 from natural product 1 via isobutyl ester hydrolysis and allyl protection.
Fig. 6 C3”-OH acylation of 5. Initial catalyst evaluation to access C3”-acylated fidaxomicin derivatives.
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Fig. 7 Scope of selective C3”-functionalization of 5. Acylation of 5 applying the optimized catalyst system with various acyl chlorides.
Fig. 8 Minimum inhibitory concentrations (MIC) values. Determination of the MIC in µg/mL against a panel of different C. difficile strains and M.
tuberculosis. RT Ribotype.
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concentration (MIC) and are summarized in Fig. 8. The MIC
values for C. difficile were determined using the broth micro-
dilution assay and determination of bacterial growth by obser-
vation of turbitity (MIC90)59,60. The values againstM. tuberculosis
were evaluated using a recently developed method on a GFP-
expressing M. tuberculosis strain and observation of growth by
fluorescence61. A fluorescence reduction of 90% as compared to
the no-drug control was reported as MIC90 (for details see Sup-
plementary Information, section Determination of the minimum
inhibitory concentration). All compounds were evaluated against
M. tuberculosis as well as ten C. difficile isolates. As expected with
previously reported data, OP1118 (4) displayed reduced anti-
bacterial activity, pointing out the pivotal role of the isobutyric
ester moiety for the bioactivity. Intriguingly, aromatic derivatives
7a–7f showed similar bioactivities than for OP1118 (4). Inter-
estingly, C2”-benzoylated derivatives 7d–f–C2 were found to be
less active than the C3”-benzoylated analogs that supports
hypotheses drawn from the cryo-EM structural analysis. To our
delight, heteroaromatic derivatives 7j–n were found to have good
bioactivity for all the tested bacterial strains compared to the
aromatic series 7a to 7f–C2. Noteworthy, derivative 7j is highly
active against M. tuberculosis (MIC= 0.5 µg/mL) as well as the C.
difficile strains; therefore, the latter represents an excellent land-
mark for implementation of substitution on the furan moiety.
Unfortunately, first decorated versions 7p–r of the more potent
heteroaromatic derivative 7j were found to be less active, such as
the derivatives 7q–r, which are sterically more demanding.
Nevertheless, this first batch of substituted furan derivatives
indicated that smaller functional groups and/or functionalizations
at the position 4 of the furan should be considered in the future
for the modification of derivative 7r. On the other hand, con-
sidering the reported bioactivities of tiacumicin F (7u), non-
aromatic C3”-acylated fidaxomicin derivatives were expected to
have similar or improved bioactivities. Indeed, fidaxomicin ana-
logs 7s-ah were found to have good bioactivity, and especially,
derivatives 7w–x. Whereas derivatives 7j, 7u, and 7x have
excellent bioactivities against all tested bacterial strains, these are
slightly less potent than fidaxomicin itself. Nevertheless, this
study validates our hypothesis and a fine-tuning of those
derivatives may pave the way to discover more potent antibiotic
derivatives.
Allylic substitution of the rhamnose-resorcylate moiety. Over
the past 50 years, metal-catalyzed allylic (asymmetric) substitu-
tion emerged as an extremely appealing and efficient tool to form
C-C and C-heteroatom bonds with applications in target-oriented
synthesis of natural products and active pharmaceutical
ingredients62. Whereas numerous developments allow the use of
a broad range of allylic substrates, the use of allylic acetals as allyl
donors remains scarce and were used as carbon sources in
palladium-catalyzed umpolung allylations63,64. Nonetheless, these
reports led us to consider the allylic noviose and the allylic
rhamnose of fidaxomicin as potential electrophilic partner in
metal-catalyzed allylic substitution. Considering the steric con-
gestion around the allylic noviose moiety as well as the electro-
nically favored environment around the rhamnose due to the
proximity to the conjugated macrolactone, we envisioned that
discrimination of the allylic rhamnose versus allylic noviose
would be possible. Moreover, using an appropriate oxygen
nucleophile would lead, after deprotection, to 8 that represents a
unique platform for glycodiversification (Fig. 9).
Unfortunately, extensive screening with differently protected
O-nucleophiles remained unsuccessful as either no conversion or
complex mixtures were obtained. This prompted us to consider
other types of nucleophiles. To our delight, we were pleased to
find that C-nucleophiles were competent, thus validating our
strategy (Fig. 10). Cyclic 1,3-dicarbonyls, such as 9, 10, and 11
were synthesized with concomitant isomerization of the diene
moiety (between C4 and C5), which is in line with the ability of
palladium to migrate along a π system65. Whereas substitution
with N,N-dimethyl barbituric acid and dimedone required
temperatures of 90 °C, the reaction with Meldrum’s acid led to
decomposition; however, lowering the temperature to 70 °C was
beneficial to provide the desired product 11 in 27% yield.
Unfortunately, extensive screening of the parameters of the
reaction with special emphasis on phosphine ligand did not
improve the reaction further and isomerization of the double
bond could not be prevented. Noteworthy, we ruled out a
Fig. 9 Site-selective allylic functionalization of (1). Overview of the strategy.
Fig. 10 Allylic substitution of the rhamnose-resorcylate moiety. Scope of the site-selective allylic functionalization of (1).
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plausible Baylis–Hillman type mechanism by control experiments
(see Supplementary Information, section Experimental proce-
dures Tsuji–Trost functionalizations).
Therefore, to best of our knowledge, this transformation
represents a unique palladium-catalyzed allylic substitution with
such a complex electrophilic partner. Moreover, given the
abundance of allylic glycoside derivatives in biologically active
natural products (especially in polyene macrolides), we believe
that this finding will pave the way for further development in
drug discovery66. Next, we decided to take advantage of the
Meldrum’s acid derivative 11. Upon hydrolysis and decarboxyla-
tion of the Meldrum’s acid moiety, carboxylic acid 13 was
obtained in 35% yield over two steps (Fig. 11). Usually,
Meldrum’s acid 11 was directly submitted to hydrolysis without
further purification due to the difficult separation of 11 from its E,
Z-isomer, which is formed in 12% yield as a by-product of the
Tsuji–Trost reaction. The carboxylic acid 13 acts as suitable
functional group for a great variety of transformations such as
esterification/amide coupling, reduction, Curtius rearrangement,
or decarboxylative brominations and consequently allowing the
synthesis of analogs with one or two additional CH2-groups,
which are difficult or not even possible to obtain by fermentation
of a genetically modified producer strain.
As we were able to regain high quantities of the cleaved
rhamnose-orsellinate moiety 12 after the Tsuji–Trost reaction, we
prepared C2- and C1-elongated fidaxomicin analogs, starting
from fidaxomicin (1). Therefore, we addressed the selective
reduction of the carboxylic acid 13 next. Upon screening of
several conditions, we found that formation of the mixed
anhydride using isobutyl chloroformate and subsequent reduc-
tion with NaBH4 yields the desired alcohol 15, besides some
traces of competing isobutyl ester cleavage on the noviose part67.
Transformation of the rhamnosyl-orsellinate 12 into a suitable
glycosyl donor was achieved via allyl protection of the phenolic
hydroxy groups, followed by substitution of the anomeric
hydroxy group by bromide using HBr to give glycosyl bromide
14 as a single anomer. With glycosyl bromide 14 and alcohol 15
in hands, we performed the glycosylation using Königs–Knorr
conditions68 that gave after allyl deprotection, the desired C2-
elongated fidaxomicin 17. Besides glycosylation on the primary
alcohol, minor amounts of glycosylation at C7- and C18 hydroxy
groups were observed as well, which accounts for the relatively
low yield. The desired C2-elongated fidaxomicin 17 was
surprisingly obtained as a single anomer. NOESY spectra as well
as similar 1JCH coupling constants (1: 1JCH= 155 Hz, 17: 1JCH=
157 Hz) indicate that most probably β-glycosylation
occurred69,70. NOESY analysis of the glycosyl bromide 14,
however, revealed that the α-anomer was obtained as the major
isomer, indicating an SN2-type mechanism (see Supplementary
Figs. 1, 88, 100, and 101)
Furthermore, we investigated decarboxylative brominations
via a Barton ester to give bromide 16. Best yields were
achieved when Barton ester formation was performed using
the coupling reagent HOTT71–73 directly followed by addition of
Fig. 11 Synthesis of C2- and C1-elongated fidaxomicin analogs. Detailed synthetic route toward C2- and C1-elongated fidaxomicin analogs 17 and 18. IBCF
Isobutyl chloroformate, HOTT S-(1-oxido-2-pyridinyl)−1,1,3,3-tetramethylthiouronium hexafluorophosphate.
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bromotrichloromethane74. The following hydrolysis of bromide
16 was found to be troublesome75. Various by-products that
originate from transesterifications on the macrolactone were
observed and made purification difficult. Upon optimization,
yields of up to 44% of the desired alcohol were obtained. Final
glycosylation reaction, which had to be warmed to 40 °C in order
to get complete conversion, and allyl deprotection then yielded
the C1-elongated fidaxomicin 18.
As already outlined before, the carboxylic acid 13 as well as
the alcohol 15 and 16.1 can serve as a platform for further
modifications. As we are interested in the role of the sugar moieties
on fidaxomicin, we investigated displacement by other sugar
moieties on this stage. As a suitable carbohydrate, we choose
glycosylamine, which could be coupled to the carboxylic acid
moiety using HATU to afford the desired glycosylamide 19 in high
yields (Fig. 12). On the another hand, we envisioned to introduce
1,2,3-triazole scaffolds, which are relatively stable to hydrolytic
conditions, metabolic degradation, and redox conditions. More-
over, they are known to be bioisosteres of numerous functional
groups and they are prone to H-bonds and π–π stackings
interactions. All these features rendering 1,2,3-triazole ring highly
attractive to access lead compounds in medicinal chemistry76–78.
Whereas activation of the alcohol 15 through sulfonate formation
followed by sodium azide displacement was unselective, we
found out that the one-pot azidation of alcohol 15 using bis
(p-nitrophenyl) phosphorazidate was highly selective for the
primary alcohol79. Subsequent Cu-mediated cycloaddition deliv-
ered the triazole 20 in good overall yield. Unfortunately,
reproducibility issues with the azidation step prompt us to
consider another sequence. After optimization, the alcohol 15
was fully converted to the desired phosphate using bis-(2,4-
dichlorophenyl) chlorophosphate. Upon SN2-type mechanism
with sodium azide followed by previously used CuAAC with
1-ethynyl-4-methylbenzene, the triazole 20 was obtained in an
acceptable yield. Gratifyingly, due to the highly selective activation
of the primary alcohol of 15, this strategy would allow us to
obtain an expeditious library of C2-elongated fidaxomicin analogs
via SN2-type mechanism by varying the nucleophile.
Biological evaluation of rhamnose-edited fidaxomicin deriva-
tives. The biological activities for these compounds bearing var-
iations on the rhamnose-homoorsellinate part are summarized
in Fig. 13. While fidaxomicin (1) is highly active against
M. tuberculosis (MIC= 0.25 µg/mL) and C. difficile, the activity
for the C1- and C2-elongated derivatives gradually drops, thereby
indicating that binding to the RNAP is diminished probably due
to a reduced interaction of the rhamnose sugar with Arg89.
Therefore, we conclude that the position of the rhamnose-
resorcylate moiety is crucial for the excellent activity of fidax-
omicin (1) due to optimal interactions with amino acid residues
in the binding pocket.
Interestingly, derivatives 11 and 19, where the rhamnose
moiety is exchanged by Meldrum’s acid and glycosylamine,
respectively, are still active against M. tuberculosis, even though
the activity significantly decreased. However, activity against
C. difficile was lost. To our delight, triazole 20, whose structure
considerably differs from fidaxomicin, still features good activity
against M. tuberculosis.
Conclusion
In conclusion, we achieved the synthesis of a variety of novel
fidaxomicin derivatives based on structural information provided
by cryo-EM structures of fidaxomicin binding to the target bac-
terial RNAP. A highly site-selective method for the acylation of
the noviose moiety using Shimada’s catalyst gave access to 30
novel fidaxomicin analogs with modifications on the 3”-OH
group. These derivatives showed similar antibacterial activities
compared to natural product 1 and thereby confirming our
hypothesis that modifications in these positions are beneficial in
retaining activity. In addition, our search for new reactions
regarding fidaxomicin resulted in the development of a
Tsuji–Trost type allylic substitution with cyclic 1,3-diketones to
furnish rhamnose-resorcylate cleavage and thereby giving access
to carboxylic acid 13 that would serve as a basis for a variety of
glycodiversifications such as 19. Furthermore, triazole 20 retained
some antibacterial activity and therefore use of these azide pre-
cursors represents a promising platform for further derivatiza-
tions. At present, this Tsuji–Trost approach is limited to C-
nucleophiles, but investigations to broaden the scope of this
reaction are currently under investigation and will be reported in
due course. Applying this reaction, C1- and C2-elongated fidax-
omicin analogs 17 and 18 were synthesized, thus representing the
first examples of a complex, multi-step modification of natural
antibiotic fidaxomicin (1). These new fidaxomicin derivatives and
further derivatives prepared by the methods described in this
work may prove to be promising, future candidates for the
treatment of bacterial infections and may contribute to ongoing
efforts to reduce rate of resistance development.
Methods
Full methods and data are given in the Supplementary Material, see Supplementary
Methods section.
Fig. 12 Functionalization of C2-elongated carboxylic acid 13 and alcohol 15. Synthesis of glucosamide-fidaxomicin 19 and triazol 20. HATU 1-[Bis
(dimethylamino)methylene]−1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, DPPA-NO2Di-(nitrophenyl)phosphoryl azide.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Compounds and the corresponding biological data were deposited at PubChem and
PubChem BioAssay (SID 440785998–440786033). Procedures and analytical data,
including NMR spectra, are available in the Supplementary Information or can be
requested from the corresponding author.
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